Molecular targets on the horizon for kidney and urothelial cancer

Nature Reviews Clinical Oncology

Volumn 10, Issue 10, 2013, Pages 557-570

  Bellmunt, Joaquim ^a,b   Teh, Bin T ^c   Tortora, Giampaolo ^d   Rosenberg, Jonathan E ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; CETUXIMAB; CISPLATIN; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 3; GEFITINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 8; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN SWI; SCATTER FACTOR; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR SNF; TRASTUZUMAB; TUMOR MARKER; UBIQUITIN; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN;

BLOOD TOXICITY; CANCER RESISTANCE; CARCINOGENESIS; CARDIOTOXICITY; CLEAR CELL CARCINOMA; COMPLEX FORMATION; DRUG POTENTIATION; DRUG SAFETY; EPIGENETICS; GENE CONTROL; GENE SEQUENCE; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; HYPOXIA; HYPOXIA INDUCIBLE FACTOR GENE; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SNF GENE; SWI GENE; TRANSITIONAL CELL CARCINOMA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VHL GENE;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84885020425     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.155     Document Type: Review

References (187)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
3. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
4. Lehmann, J. et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J. Clin. Oncol. 23, 4963-4974 (2005). (Pubitemid 46224002)
5. Parekh, D. J., Bochner, B. H. & Dalbagni, G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J. Clin. Oncol. 24, 5519-5527 (2006). (Pubitemid 46631332)
6. McConkey, D. J. et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol. Oncol. 28, 429-440 (2010).
7. Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978-984 (2010).
8. Sidransky, D. et al. Clonal origin bladder cancer. N. Engl. J. Med. 326, 737-740 (1992).
9. Loehrer, P. J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
10. Bajorin, D. F. et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999). (Pubitemid 29470648)
11. Bellmunt, J. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28, 1850-1855 (2010).
12. Kamat, A. M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 63, 4-15 (2013).
13. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993). (Pubitemid 23231974)
14. Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. 19, 617-623 (2011).
15. Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674-4681 (2009).
16. Yao, M. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569-1575 (2002). (Pubitemid 35277281)
17. Choueiri, T. K. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860-865 (2008).
18. Zimmer, M. et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838-848 (2008).
19. Alimov, A., Sundelin, B., Wang, N., Larsson, C. & Bergerheim, U. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int. J. Oncol. 25, 179-185 (2004).
20. Shen, C. et al. Genetic and functional studies implicate HIF1? as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222-235 (2011).
21. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999). (Pubitemid 29246458)
22. Gordan, J. D. et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446 (2008).
23. Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002). (Pubitemid 41039126)
24. Yan, Q., Bartz, S., Mao, M., Li, L. & Kaelin, W. G. Jr. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol. Cell. Biol. 27, 2092-2102 (2007). (Pubitemid 46418467)
25. Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol. Cancer Res. 2, 89-95 (2004). (Pubitemid 38250425)
26. Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002). (Pubitemid 41039149)
27. Covello, K. L. et al. HIF-2? regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557-570 (2006). (Pubitemid 43345322)
28. Keith, B., Johnson, R. S. & Simon, M. C. HIF1f and HIF2r: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2012).
29. Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M. & Gudas, L. J. Activation of HIF2? in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res. 73, 2916-2925 (2013).
30. Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2? is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).
31. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002). (Pubitemid 41039148)
32. Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25, 5675-5686 (2005). (Pubitemid 40853601)
33. Chan, D. A. et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70 (2011).
34. Maru, S. et al. Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2? expression in human renal cell carcinoma. J. Urol. 189, 1921-1929 (2013).
35. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
36. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
37. Kapur, P. et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 14, 159-167 (2013).
38. Peña-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751-759 (2012).
39. Reisman, D., Glaros, S. & Thompson, E. A. The SWI/SNF complex and cancer. Oncogene 28, 1653-1668 (2009).
40. Weissman, B. & Knudsen, K. E. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 69, 8223-8230 (2009).
41. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
42. Lichner, Z. et al. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am. J. Pathol. 182, 1163-1170 (2013).
43. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
44. Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44, 17-19 (2011).
45. Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor. Mol. Cell Biol. 29, 2181-2192 (2009).
46. Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature 465, 243-247 (2010).
47. Niu, X. et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31, 776-786 (2012).
48. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
49. Lopez-Beltran, A. et al. Pathology of renal cell carcinoma: an update. Anal. Quant. Cytol. Histol. 35, 61-76 (2013).
50. Delahunt, B. et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol. 32, 590-595 (2001). (Pubitemid 32601240)
51. Waldert, M. et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 102, 1381-1384 (2008).
52. Bellon, S. F. et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 283, 2675-2683 (2008).
53. Looyenga, B. D. et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc. Natl Acad. Sci. USA 108, 1439-1444 (2011).
54. Sanders, M. E., Mick, R., Tomaszewski, J. E. & Barr, F. G. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am. J. Pathol. 161, 997-1005 (2002). (Pubitemid 34988387)
55. Refae, M. A., Wong, N., Patenaude, F., Bégin, L. R. & Foulkes, W. D. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat. Clin. Pract. Oncol. 4, 256-261 (2007). (Pubitemid 46510535)
56. Toro, J. R. et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J. Med. Genet. 45, 321-331 (2008). (Pubitemid 351839472)
57. Gardie, B. et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J. Med. Genet. 48, 226-234 (2011).
58. Furge, K. A. et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 67, 3171-3176 (2007). (Pubitemid 46724854)
59. Prowse, A. H. et al. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am. J. Hum. Genet. 60, 765-771 (1997). (Pubitemid 27146484)
60. Hori, Y. et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J. Pathol. 212, 218-226 (2007). (Pubitemid 46852100)
61. Morrissey, C. et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 61, 7277-7281 (2001). (Pubitemid 32946526)
62. Costa, V. L. et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7, 133 (2007).
63. Awakura, Y., Nakamura, E., Ito, N., Kamoto, T. & Ogawa, O. Methylation-associated silencing of TU3A in human cancers. Int. J. Oncol. 33, 893-899 (2008).
64. Kvasha, S. et al. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett. 265, 250-257 (2008).
65. Hirata, H. et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int. J. Cancer 128, 1793-1803 (2011).
66. Rogenhofer, S. et al. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 109, 459-465 (2012).
67. Escudier, B., Szczylik, C., Porta, C. & Gore, M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat. Rev. Clin. Oncol. 9, 327-337 (2012).
68. Kelly, R. J., Billemont, B. & Rixe, O. Renal toxicity of targeted therapies. Target. Oncol. 4, 121-133 (2009).
69. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
70. Hu-Lowe, D. D. et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2. Clin. Cancer Res. 14, 7272-7283 (2008).
71. Heng, D. Y. et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23, 1549-1555 (2012).
72. Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005). (Pubitemid 41443415)
73. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010).
74. Rapisarda, A. & Melillo, G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9, 378-390 (2012).
75. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
76. Huang, D. et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063-1071 (2010).
77. Welti, J. C. et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30, 1183-1193 (2011).
78. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01223027 (2013).
79. Xu, C. F. et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol. 29, 2557-2564 (2011).
80. Choueiri, T. K. et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181-186 (2013).
81. Choueiri, T. K. et al. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC) [abstract]. J. Clin. Oncol. 30 (Suppl. 5), a364 (2012).
82. Carbone, C. et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin. Cancer Res. 17, 5822-5832 (2011).
83. Sievert, K. et al. Economic aspects of bladder cancer: what are the benefits and costs? World J. Urol. 27, 295-300 (2009).
84. Gakis, G. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 45-57 (2013).
85. Burger, M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36-44 (2013).
86. Sternberg, C. N. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur. Urol. 63, 58-66 (2013).
87. Bellmunt, J. & Petrylak, D. P. New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598-607 (2012).
88. Sanchez-Carbayo, M. & Cordon-Cardo, C. Applications of array technology: identification of molecular targets in bladder cancer. Br. J. Cancer 89, 2172-2177 (2003). (Pubitemid 38167995)
89. Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377-3386 (2012).
90. Sjodahl, G. et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 6, e18583 (2011).
91. Lindgren, D. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7, e38863 (2012).
92. Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463-3472 (2010).
93. Milowsky, M. I. et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 112, 462-470 (2013).
94. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
95. Iyer, G. et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. http://dx.doi.org/10. 1200/JCO.2012.46.5740.
96. Wang, Z. & Sun, Y. Targeting p53 for novel anticancer therapy. Transl. Oncol. 3, 1-12 (2010).
97. Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878 (2011).
98. National Cancer Institute. The Cancer Genome Atlas [online], http://cancergenome.nih.gov/(2012).
99. Bellmunt, J., Hussain, M. & Dinney, C. P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit. Rev. Oncol. Hematol. 46 (Suppl.), S85-S104 (2003). (Pubitemid 36808975)
100. Nutt, J. E., Lazarowicz, H. P., Mellon, J. K. & Lunec, J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br. J. Cancer 90, 1679-1685 (2004). (Pubitemid 38648256)
101. Ruck, A. & Paulie, S. EGF, TGF alpha, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res. 18, 1447-1452 (1998). (Pubitemid 28342544)
102. Perrotte, P. et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999). (Pubitemid 29085177)
103. Bambury, R. M. & Rosenberg, J. E. Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. Front. Pharmacol. 4, 3 (2013).
104. Petrylak, D. P. et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 105, 317-321 (2010).
105. Pruthi, R. S. et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 106, 349-354 (2010).
106. Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531 (2009).
107. Philips, G. K. et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann. Oncol. 20, 1074-1079 (2009).
108. Grivas, P. et al. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a4506 (2012).
109. Inoue, K. et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-4884 (2000). (Pubitemid 32110432)
110. Wong, Y. N. et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J. Clin. Oncol. 30, 3545-3551 (2012).
111. Black, P. C. et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin. Cancer Res. 14, 1478-1486 (2008). (Pubitemid 351413932)
112. McConkey, D. J. et al. HDAC inhibitors reverse epithelial-to-mesenchymal transition (EMT) and restore sensitivity to EGFR inhibitors in urothelial carcinoma cells [abstract]. ASCO Genitourinary Cancers Symp. a267 (2009).
113. Laé, M. et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in patients. Ann. Oncol. 21, 815-819 (2010).
114. Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E. & Thalmann, G. N. HER2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 60, 350-357 (2011).
115. Galsky, M. D. et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest. New Drugs 30, 695-701 (2012).
116. Hussain, M. H. et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218-2224 (2007). (Pubitemid 46954646)
117. Beuzeboc, P. et al. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study [abstract]. J. Clin. Oncol. 25 (Suppl.), a15565 (2007).
118. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01353222 (2013).
119. Wülfing, C. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881-2890 (2009).
120. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00949455 (2012).
121. Iyer, G. & Milowsky, M. I. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol. Oncol. 31, 303-311, (2013).
122. Lamont, F. R. et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 104, 75-82 (2011).
123. Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959 (2001). (Pubitemid 32545179)
124. van Rhijn, B. W. et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187, 310-314 (2012).
125. van Oers, J. M. et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol. 55, 650-657 (2009).
126. Rebouissou, S. et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J. Pathol. 227, 315-324 (2012).
127. van Rhijn, B. W. et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64, 1911-1914 (2004). (Pubitemid 38339432)
128. Milowsky, M. et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 [abstract]. J. Clin. Oncol. 31 (Suppl. 6), a255 (2013).
129. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01732107 (2013).
130. Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795-803 (2013).
131. Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083 (2010).
132. Platt, F. M. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 15, 6008-6017 (2009).
133. López-Knowles, E. et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66, 7401-7404 (2006). (Pubitemid 44289191)
134. Ching, C. B. & Hansel, D. E. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest. 90, 1406-1414 (2010).
135. Kompier, L. C. et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5, e13821 (2010).
136. Knowles, M. A., Platt, F. M., Ross, R. L. & Hurst, C. D. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 28, 305-316 (2009).
137. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01551030 (2013).
138. Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290 (2012).
139. Munster, P. et al. PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select patient (PT) populations defined by predictive markers (study P3K112826) [abstract]. Ann. Oncol. 23 (Suppl. 9), a4420 (2012).
140. Gomez-Pinillos, A. & Ferrari, A. C. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol. Oncol. Clin. North Am. 26, 483-505 (2012).
141. Seront, E. et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann. Oncol. 23, 2663-2670 (2012).
142. Milowsky, M. I. et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium [abstract]. J. Clin. Oncol. 29 (Suppl.), a4606 (2011).
143. Guo, Y. et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J. Pathol. 230, 17-27 (2013).
144. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01215136 (2013).
145. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00933374 (2012).
146. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00949949 (2013).
147. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01184326 (2013).
148. Kopparapu, P. K. et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 33, 2381-2390 (2013).
149. Inoue, K. et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 60, 2290-2299 (2000). (Pubitemid 30225196)
150. Allen, L. E. & Maher, P. A. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J. Cell Physiol. 155, 368-375 (1993). (Pubitemid 23134875)
151. Afonso, J., Santos, L. L., Amaro, T., Lobo, F. & Longatto-Filho, A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion-the prognostic contribution of related molecular markers. Histopathology 55, 514-524 (2009).
152. Dreicer, R. et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115, 4090-4095 (2009).
153. Sridhar, S. S. et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest. New Drugs 29, 1045-1049 (2011).
154. Sonpavde, G. et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol. Oncol. 27, 391-399 (2009).
155. Gallagher, D. J. et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol. 28, 1373-1379 (2010).
156. Bellmunt, J. et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 22, 2646-2653 (2011).
157. Galsky, M. D. et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin. Genitourin. Cancer 11, 175-181 (2013).
158. Grivas, P. et al. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a265 (2012).
159. Necchi, A. et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 13, 810-816 (2012).
160. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01622660 (2013).
161. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01108055 (2013).
162. Choueiri, T. K. et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol. 30, 507-512 (2012).
163. Hahn, N. M. et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 29, 1525-1530 (2011).
164. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00942331 (2013).
165. Balar, A. V. et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J. Clin. Oncol. 31, 724-730 (2013).
166. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00407485 (2013).
167. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01441050 (2013).
168. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01342172 (2012).
169. Richardson, P. G. et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152, 367-379 (2011).
170. Kamada, M. et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 6, 299-308 (2007). (Pubitemid 46206694)
171. Kanagasabai, R. et al. Hsp27 protects adenocarcinoma cells from UV-induced apoptosis by Akt and p21-dependent pathways of survival. Mol. Cancer Res. 8, 1399-1412 (2010).
172. Concannon, C. G., Gorman, A. M. & Samali, A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8, 61-70 (2003). (Pubitemid 36133139)
173. Bruey, J. M. et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2, 645-652 (2000).
174. Hayashi, N. et al. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ. 19, 990-1002 (2012).
175. Garg, M. et al. Heat-shock protein 70-72 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur. J. Cancer 46, 207-215 (2010).
176. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01454089 (2013).
177. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01780545 (2013).
178. Sonpavde, G. & Choueiri, T. K. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br. J. Cancer 107, 1009-1016 (2012).
179. Patel, P. H. et al. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract]. J. Clin. Oncol. 26 (Suppl. 15), a5008 (2008).
180. McDermott, D. F. et al. The high-dose aldesleukin (HD IL-2) 'SELECT' trial in patients with metastatic renal cell carcinoma [abstract]. J. Clin. Oncol. 28 (Suppl.), a4514 (2010).
181. Rini, B. I. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3743-3748 (2008).
182. Hutson, T. E. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract]. J. Clin. Oncol. 26 (Suppl.), a5046 (2008).
183. Tran, H. T. et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 13, 827-837 (2012).
184. Zurita, A. J. et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 23, 46-52 (2012).
185. Kim, J. J. et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118, 1946-1954 (2012).
186. Rini, B. I. et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin. Cancer Res. 17, 3841-3849 (2011).
187. Wulfing, C. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881-2890 (2009).